In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.

Hasaya DokduangWassana JamnongkarnBundit PromraksaManida SuksawatSureerat PadthaisongMalinee ThaneeJutarop PhetcharaburaninNisana Namwat Sakkarn SangkhamanonAttapol TitapunNarong Khuntikeo Poramate KlanritWatcharin Loilome

Published in: Drug design, development and therapy (2020)

Our study indicates that varlitinib is a promising therapeutic agent for CCA treatment via the inhibition of EGFR/HER2. The anti-tumor effect of varlitinib on CCA also showed synergism in combination with PI3K inhibition. Aspartate metabolite level was correlated with varlitinib response. Combination of varlitinib with targeted drug or cytotoxic drug was recommended.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
adverse drug
cancer therapy
emergency department
drug induced
replacement therapy
smoking cessation